Cipla wins Rs 1170 cr tender to supply HIV drugs from Global Fund

The Mumbai-based pharma major Cipla has been awarded $ 188.95 million (about Rs 1174.79 crore) contract by Global Fund for supplying anti-retrovirals (ARV) drugs. Cipla has been selected as a ‘Panel Supplier’ for a supplier partnership agreement. The contract is effective from January 1, 2015 and will run for a period of three years. The supplies are expected to begin from fourth quarter of FY 2015.
 
Cipla has a long-term association with Global Fund since 2002. Last year, Cipla has been one of the suppliers who has been awarded with a long-term contract for supplying anti-malarial drugs.
 
The anti-retrovirals drugs will be manufactured in Cipla’s state-of-the-art manufacturing facilities in India, which has been approved by various international regulatory agencies.
 
Subhanu Saxena, MD & Global CEO, Cipla Limited, said, “We are extremely proud to have won this tender from Global Fund. Cipla has been committed to the cause of HIV/AIDS for over two decades and this tender offers us a great opportunity to make HIV/AIDS treatment accessible to more than 140 countries through Global Fund.”
 
The Global Fund - which adopts a partnership model to accelerate the end of AIDS, tuberculosis and malaria as epidemics - raises and invests nearly $4 billion a year to support programs run by local experts in more than 140 countries. Created in 2002, the Global Fund operates as a partnership between governments, civil society, the private sector and people affected by the diseases. Programs supported by the Global Fund have put 7.3 million people on antiretroviral therapy for HIV, have tested and treated 12.3 million people for TB, and have distributed 450 million mosquito nets to protect families against malaria.